SCHEMBL6085409

SCHEMBL6085409

COc1cc(CC(=O)Nc2ccc(-c3n[nH]cc3-c3nc4ccc(C)cc4o3)cc2)cc(OC)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.55
SMN1; SMN2 Q16637 6/20 0.55
POLB P06746 3/20 0.55
CETP P11597 1/20 0.52
P2RY14 Q15391 2/20 0.48
KDM4E B2RXH2 4/20 0.47
HPGD P15428 4/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
HSD17B10 Q99714 3/20 0.47
USP2 O75604 3/20 0.47
ALDH1A1 P00352 3/20 0.47
RXFP1 Q9HBX9 2/20 0.47
GAA P10253 2/20 0.47
PPARG P37231 1/20 0.47
NCOA2 Q15596 1/20 0.47
NCOA1 Q15788 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CACNA1B Q00975 1/20 0.47
APBA1 Q02410 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085102 0.90 MAPT (0.54) MAPTSMN1; SMN2POLBCETPKDM4E
SCHEMBL6083661 0.84 CEPT1 (0.54) MAPTSMN1; SMN2CETPP2RY14KDM4E
SCHEMBL6085234 0.83 MAPT (0.57) MAPTSMN1; SMN2POLBCETPKDM4E
SCHEMBL6084754 0.83 MAPT (0.67) MAPTSMN1; SMN2POLBCETPP2RY14
SCHEMBL6086216 0.83 P2RY14 (0.63) MAPTSMN1; SMN2P2RY14MEN1KMT2A
SCHEMBL6085354 0.82 MAPT (0.51) MAPTSMN1; SMN2POLBCETPRXFP1
SCHEMBL6086486 0.82 MAPT (0.51) MAPTSMN1; SMN2POLBCETPKDM4E
SCHEMBL6085490 0.81 P2RY14 (0.67) MAPTSMN1; SMN2P2RY14RXFP1KDR
SCHEMBL6083537 0.81 P2RY14 (0.61) MAPTSMN1; SMN2P2RY14HSD17B10KDR
SCHEMBL6085381 0.81 CETP (0.56) MAPTSMN1; SMN2POLBCETPP2RY14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 MAPT 801/4885SMN1; SMN2 831/4885POLB 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.